β‐adrenoceptor subtypes mediating the airways response to BRL 35135 in man
- 1 December 1993
- journal article
- clinical trial
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 36 (6) , 567-571
- https://doi.org/10.1111/j.1365-2125.1993.tb00416.x
Abstract
1 The purpose of the study was to assess the bronchorelaxant effects of the beta3-adrenoceptor agonist BRL 35135 in normal human airways. 2 Eight healthy male subjects were studied, having previously demonstrated airways responsiveness to inhaled salbutamol 200 microg, with a group mean (+/- s.e. mean) fall in airways resistance (Raw), from baseline, of 37 +/- 5%. 3 Subjects attended the laboratory on 3 separate days, having fasted and taken placebo (PL) or nadolol 20 mg (N20), 2 h previously. 4 After 30 min rest, baseline measurements of Raw, serum potassium, glucose and free fatty acid were performed before subjects were given single oral doses of BRL 35135 8 mg (BRL) or placebo BRL. Measurements were repeated 60 min after the BRL or placebo BRL were given. 5 There was a significant (P < 0.05) fall in Raw (% change from baseline, as means and 95% CI) with PL/BRL: -32(-18, -46), compared with either PL/PL: -8(5, -21), or N20/BRL: -11(2, -24). There was no significant difference between PL/PL and N20/BRL. 6 A similar pattern to Raw was observed for both of the beta2-mediated metabolic responses which were also antagonised by nadolol. For the potassium response (mmol l(-1)), there was a significant (P < 0.05) difference between PL/BRL: -0.50(-0.31, -0.69), in comparison with either PL/PL: 0.08(-0.11, 0.27) or N20/BRL: 0.09(-0.10, 0.28), but values for PL/PL and N20/BRL were not significantly different. In contrast, with the free fatty acid response (nmol 1(-1)), the increase seen with N20/BRL: 85(1.0, 171.0) was significantly (P < 0.05) different from PL/PL: 3.7(-82.3, 89.8), but was not different from PL/BRL: 132.5(46.5, 218.5). 7 In conclusion, BRL 35135 produced airways, potassium and glucose responses which were antagonised by nadolol, whereas the lipolysis response was not. This suggests that there are not functional beta3-adrenoceptors in human airways.Keywords
This publication has 21 references indexed in Scilit:
- Discrepancies in Lipolytic Activities Induced by β-Adrenoceptor Agonists in Human and Rat AdipocytesHormone and Metabolic Research, 1990
- Molecular Characterization of the Human β 3 -Adrenergic ReceptorScience, 1989
- Statistics on microcomputers. A non-algebraic guide to their appropriate use in biomedical research and pathology practice. 3. Analysis of variance and distribution-free methods.Journal of Clinical Pathology, 1988
- The rat lipolytic β-adrenoceptor: Studies using novel β-adrenoceptor agonistsEuropean Journal of Pharmacology, 1984
- Atypical β-adrenoceptor on brown adipocytes as target for anti-obesity drugsNature, 1984
- β-adrenoceptor studies. 6. Further investigations on the hybrid nature of the rat adipocyte β-adrenoceptorEuropean Journal of Pharmacology, 1980
- Differences in Metabolic Responses to β‐Adrenergic Stimulation after Propranolol or Metoprolol AdministrationActa Medica Scandinavica, 1979
- β-adrenoceptor studoes. III On the β-adrenoceptors in rat adipose tissueEuropean Journal of Pharmacology, 1974
- A NEW METHOD FOR MEASURING AIRWAY RESISTANCE IN MAN USING A BODY PLETHYSMOGRAPH: VALUES IN NORMAL SUBJECTS AND IN PATIENTS WITH RESPIRATORY DISEASE 1Journal of Clinical Investigation, 1956
- A RAPID PLETHYSMOGRAPHIC METHOD FOR MEASURING THORACIC GAS VOLUME: A COMPARISON WITH A NITROGEN WASHOUT METHOD FOR MEASURING FUNCTIONAL RESIDUAL CAPACITY IN NORMAL SUBJECTS 1Journal of Clinical Investigation, 1956